Qureight's Ai 3d Imaging Platform To Support Calluna Pharma's Phase 2 Aurora Study Of Cal101 In Idiopathic Pulmonary Fibrosis (ipf)

Aug 27 2025

Qureight, a techbio institution advancing nan knowing of lung and bosom illness done exertion of its AI-powered imaging and objective information curation platform, coming announced that it has been selected by Calluna Pharma to support its Phase 2 AURORA study. Qureight will analyse imaging information from big patients, evaluating anatomical lung changes successful individuals treated pinch CAL101, Calluna's lead plus for nan curen of idiopathic pulmonary fibrosis (IPF).

The expertise to precisely and quickly measure the efficacy of a promising caller therapy is peculiarly important for diseases specified arsenic IPF, wherever location are constricted curen options disposable and nan improvement of caller therapies is hindered by nan complexities of diagnosis, monitoring and improvement pathways. Qureight's 3D image-based AI devices will beryllium utilized to quantify changes successful aggregate imaging biomarkers, arsenic good arsenic changes successful fibrosis measurement successful localised sections of nan lungs, pinch precocious sensitivity and precision. These information will supply insights into curen efficacy done monitoring illness stabilisation aliases progression. The Qureight level is capable to make contiguous results from these highly elaborate analyses, enabling faster and much businesslike objective improvement compared to accepted image-based study of objective data, which is often challenging and inaccurate.

AURORA is simply a randomised, double-blind, placebo-controlled proceedings designed to measure nan efficacy and information of CAL101 successful patients pinch IPF. The study intends to enrol 150 individuals pinch IPF crossed much than 50 sites, chiefly successful nan US, UK, EU, Turkey and South Korea. After an first 28-day screening period, patients will beryllium randomised to person 7 monthly intravenous infusions of CAL101 aliases placebo astatine a ratio of 3:2, respectively. The study's superior endpoint is lung function, measured by forced captious capacity, aliases really overmuch aerial tin forcibly beryllium exhaled, versus an individual's baseline.

We're delighted that Calluna has chosen to activity pinch america connected this adjacent shape of objective proceedings for their lead programme. Our heavy learning imaging exertion is bringing faster and much meticulous insights to beforehand nan improvement of caller therapies for lung conditions wherever location is important unmet need. The exertion of our imaging exertion arsenic portion of Calluna's objective study is testament to nan powerfulness of our attack to present meaningful analyses of efficacy. We look guardant to continuing our activity pinch nan Calluna team."

Steven Bishop, Chief Data Officer, Qureight

Jonas Hallén, MD, PhD, Co-Founder and Chief Medical Officer, Calluna Pharma, added: "The precocious announced dosing of a first diligent successful our Phase 2 AURORA study,1 marks a important milestone for Calluna, an important measurement guardant successful our effort to create caller therapies for IPF and different fibrotic and inflammatory disorders. The AURORA study is designed to show CAL101's imaginable to effect lung usability diminution and Qureight's imaging exertion will connection captious insights arsenic we measurement these cardinal outcomes."